The aducanumab trial was fraudulent. Adu binding to plaque blocked the PET tracer from binding so there was an appearance of reduced plaque in brain.
Oh yeah the person asking someone to explain/backup their claims is the idiot. Good use of logic there...
It's simple biophysics. Adu is an antibody. As an antibody, Adu would be roughly 20,000 times the size of PiB. Adu alone or as a complex with other Adu antibodies on the amyloid plaque would create steric hinderance blocking the binding of PiB.
Cafepharma is clearly the place where scientists discuss high science. Listen to us, we so smahhht, we can say amyloid!!